GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Cash Flow from Others

ORKA (Oruka Therapeutics) Cash Flow from Others : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Cash Flow from Others?

Oruka Therapeutics's cash flow from others for the six months ended in Dec. 2024 was $0.00 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.


Oruka Therapeutics Cash Flow from Others Historical Data

The historical data trend for Oruka Therapeutics's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Cash Flow from Others Chart

Oruka Therapeutics Annual Data
Trend Dec24
Cash Flow from Others
-

Oruka Therapeutics Semi-Annual Data
Dec24
Cash Flow from Others -

Oruka Therapeutics Cash Flow from Others Calculation

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Others for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Oruka Therapeutics Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


Oruka Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.